Trials / Not Yet Recruiting

Not Yet RecruitingNCT07355257

TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)

Safety and Efficacy of Telitacicept in Inflammatory Myopathies

Status: Not Yet Recruiting
Phase: Phase 2 / Phase 3
Study type: Interventional
Enrollment: 30 (estimated)

Sponsor: Zhongming Qiu · Academic / Other
Sex: All
Age: 18 Years – 75 Years
Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to evaluate the efficacy of Telitacicept in the treatment of inflammatory myopathy in patients with inflammatory diseases. The main question it aims to answer is: the safety and effectiveness of Telitacicept in treating inflammatory myopathy.

Conditions

Inflammatory Myopathy

Interventions

Type	Name	Description
DRUG	Telitacicept 240mg	On the basis of the original foundational medication regimen, add Telitacicept 240mg administered via subcutaneous injection once a week for a total of 12 weeks.

Timeline

Start date: 2026-02-02
Primary completion: 2026-12-30
Completion: 2027-03-30
First posted: 2026-01-21
Last updated: 2026-01-21

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT07355257. Inclusion in this directory is not an endorsement.